GSK
2 years ago ⋅ English ⋅ 5 min read
Newsroom
US FDA approves GSK’s Arexvy, the world’s first respiratory syncytial virus (RSV) vaccine for older adults

For media and investors only- Ground-breaking approval enables adults aged 60 years and older to be protected from RSV disease for the first time- The approval is based on data from the... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK’s respiratory syncytial virus older adult vaccine candidate gains positive European Medicines Agency CHMP opinion

For media and investors only- Positive opinion advances GSK’s goal to provide the first vaccine to help protect older adults from respiratory syncytial virus disease- Opinion is s... Read More
GSK
2 years ago ⋅ English ⋅ 3 min read
Newsroom
GSK momentum continues with strong start to 2023

For media and investors onlyFull results announcement (PDF)Download the Q1 2023 results announcementQ1 2023 results announcement (PDF, 1,019.3KB)Q1 2023 performance highlights- Sales pe... Read More
GSK
2 years ago ⋅ English ⋅ 4 min read
Newsroom
European Medicines Agency validates marketing authorisation application for Jemperli (dostarlimab) plus chemotherapy for the treatment of dMMR/MSI-H primary advanced or recurrent endometrial cancer

For media and investors only- Regulatory submission based on pivotal data from Part 1 of the RUBY phase III trialGSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agen... Read More
GSK
2 years ago ⋅ English ⋅ 7 min read
Newsroom
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health

For media and investors only- Acquisition further strengthens specialty medicines and respiratory pipeline with camlipixant, a highly selective P2X3 antagonist and potential best-in-cla... Read More
GSK
2 years ago ⋅ English ⋅ 6 min read
Newsroom
Gepotidacin’s positive phase III data shows potential to be the first in a new class of oral antibiotics for uncomplicated urinary tract infections in over 20 years

For media and investors only- Gepotidacin is a late-stage antibiotic in development in GSK’s growing infectious diseases portfolio- EAGLE-2 and EAGLE-3 phase III trials met primar... Read More